Zenas BioPharma (ZBIO) Competitors $16.71 +0.81 (+5.09%) As of 08/13/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock ZBIO vs. FOLD, BCRX, CLDX, NVAX, INVA, DVAX, MNKD, OPK, GERN, and RIGLShould you be buying Zenas BioPharma stock or one of its competitors? The main competitors of Zenas BioPharma include Amicus Therapeutics (FOLD), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX), Novavax (NVAX), Innoviva (INVA), Dynavax Technologies (DVAX), MannKind (MNKD), OPKO Health (OPK), Geron (GERN), and Rigel Pharmaceuticals (RIGL). These companies are all part of the "biotechnology" industry. Zenas BioPharma vs. Its Competitors Amicus Therapeutics BioCryst Pharmaceuticals Celldex Therapeutics Novavax Innoviva Dynavax Technologies MannKind OPKO Health Geron Rigel Pharmaceuticals Amicus Therapeutics (NASDAQ:FOLD) and Zenas BioPharma (NASDAQ:ZBIO) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, profitability, analyst recommendations, institutional ownership, valuation and dividends. Is FOLD or ZBIO more profitable? Zenas BioPharma has a net margin of 0.00% compared to Amicus Therapeutics' net margin of -6.67%. Zenas BioPharma's return on equity of 0.00% beat Amicus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-6.67% -5.07% -1.23% Zenas BioPharma N/A N/A N/A Do analysts recommend FOLD or ZBIO? Amicus Therapeutics presently has a consensus target price of $16.22, indicating a potential upside of 125.62%. Zenas BioPharma has a consensus target price of $36.67, indicating a potential upside of 119.43%. Given Amicus Therapeutics' higher possible upside, equities research analysts plainly believe Amicus Therapeutics is more favorable than Zenas BioPharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80Zenas BioPharma 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation & earnings, FOLD or ZBIO? Amicus Therapeutics has higher revenue and earnings than Zenas BioPharma. Amicus Therapeutics is trading at a lower price-to-earnings ratio than Zenas BioPharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$528.29M4.20-$56.11M-$0.12-59.92Zenas BioPharma$5M139.80-$156.99M-$3.55-4.71 Does the media favor FOLD or ZBIO? In the previous week, Zenas BioPharma had 6 more articles in the media than Amicus Therapeutics. MarketBeat recorded 8 mentions for Zenas BioPharma and 2 mentions for Amicus Therapeutics. Amicus Therapeutics' average media sentiment score of 1.19 beat Zenas BioPharma's score of 0.29 indicating that Amicus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Zenas BioPharma 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryZenas BioPharma beats Amicus Therapeutics on 7 of the 13 factors compared between the two stocks. Get Zenas BioPharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ZBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZBIO vs. The Competition Export to ExcelMetricZenas BioPharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$665.16M$3.03B$5.54B$9.82BDividend YieldN/A2.27%4.62%4.12%P/E Ratio-4.7120.6730.1526.03Price / Sales139.80363.56461.08104.76Price / CashN/A42.0537.7558.93Price / Book2.237.638.476.06Net Income-$156.99M-$54.65M$3.26B$265.11M7 Day Performance12.91%5.41%4.18%3.38%1 Month Performance30.34%7.14%4.63%2.28%1 Year PerformanceN/A31.27%34.93%29.67% Zenas BioPharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZBIOZenas BioPharma1.4955 of 5 stars$16.71+5.1%$36.67+119.4%N/A$665.16M$5M-4.71N/ANews CoverageEarnings ReportUpcoming EarningsFOLDAmicus Therapeutics4.0857 of 5 stars$6.98+4.8%$16.22+132.4%-38.7%$2.05B$528.29M-58.16480Positive NewsBCRXBioCryst Pharmaceuticals4.157 of 5 stars$8.35+1.8%$16.70+100.0%+8.1%$1.72B$450.71M-46.39530CLDXCelldex Therapeutics1.1608 of 5 stars$23.80+18.9%$51.75+117.4%-24.9%$1.33B$7.02M0.00150Positive NewsEarnings ReportHigh Trading VolumeNVAXNovavax4.7433 of 5 stars$8.48+5.6%$15.86+87.0%-27.2%$1.30B$682.16M3.721,990Analyst RevisionINVAInnoviva4.3241 of 5 stars$20.09+2.2%$42.75+112.8%+11.1%$1.23B$358.71M64.81100News CoverageAnalyst ForecastAnalyst RevisionDVAXDynavax Technologies4.2918 of 5 stars$10.58+1.0%$24.33+130.0%-2.0%$1.23B$277.25M-23.00350Earnings ReportAnalyst RevisionMNKDMannKind3.3346 of 5 stars$3.66+7.0%$9.71+165.4%-26.4%$1.05B$285.50M33.28400Analyst RevisionOPKOPKO Health4.6269 of 5 stars$1.32+1.5%$2.75+108.3%-11.2%$1.03B$713.10M0.002,997GERNGeron3.2053 of 5 stars$1.35-0.7%$4.19+210.2%-68.7%$867.70M$76.99M-10.38229Trending NewsAnalyst RevisionRIGLRigel Pharmaceuticals1.3605 of 5 stars$34.52+3.2%$38.20+10.7%+188.7%$600.18M$179.28M6.38160Gap UpHigh Trading Volume Related Companies and Tools Related Companies FOLD Alternatives BCRX Alternatives CLDX Alternatives NVAX Alternatives INVA Alternatives DVAX Alternatives MNKD Alternatives OPK Alternatives GERN Alternatives RIGL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ZBIO) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredGet This Stock NowThis company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardwa...InvestorPlace | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zenas BioPharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zenas BioPharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.